Utah’s business landscape is rich with professionals who have le...Read More
Social Media and Employers: Friends or Enemies?
The Case for HSAs
Time to Show Up
Make a Move
In the Lab
Rent to Own
Back from the Dead
A Breath of Fresh Air
Travel & Tourism
St. George – Intermountain Healthcare and Syapse, a provider of software for bringing genomics data into routine medical use, have collaborated to bring genomics-driven precision cancer care to oncologists within the Intermountain system and also worldwide. This new clinical service, Intermountain Cancer Genomics, is intended to provide cost-effective, genomics-driven, personalized treatment planning through easy-to-use software.
Intermountain Cancer Genomics provides tumor genome profiling, analysis of genomic data from a molecular tumor board, targeted therapy options, drug procurement and outcomes analysis. The service uses Intermountain’s in-house infrastructure, which includes a clinical sequencing laboratory and an affiliated health insurance plan. It uses a molecular tumor board to develop treatment options from genomic testing results, in order to procure targeted therapeutics.
Syapse software will power Intermountain Cancer Genomics. Using Syapse’s web-based interface, oncologists will be able to order molecular tests, view genomic results and molecular tumor board interpretation, make a treatment selection, and order drugs targeted to a patient’s specific genomic makeup. Syapse software integrates data from multiple source systems to provide oncologists with a unified view of their patients’ clinical and genomics data, while also tracking patient outcomes.
“Most of the patients Intermountain Cancer Genomics has treated since inception have been successfully matched with targeted therapies, resulting in improved outcomes,” said Lincoln Nadauld, director of cancer genomics at Intermountain Healthcare. “Software is critical for helping oncologists harness the power of complex genomics and clinical data, and we are excited to be working with Syapse.”